Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 0.65 |
| ▸ | CTSG | P08311 | 1/20 | 0.64 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8429826 | 1.00 | ELANE (0.65) | ELANECTSGCMA1 | |
| SCHEMBL7363457 | 1.00 | ELANE (0.65) | ELANECTSGCMA1 | |
| SCHEMBL4287233 | 1.00 | ELANE (0.65) | ELANECTSGCMA1 | |
| SCHEMBL18880036 | 0.90 | ELANE (0.68) | ELANECTSGCMA1 | |
| SCHEMBL7310675 | 0.90 | ELANE (0.80) | ELANECTSGCMA1 | |
| SCHEMBL17378380 | 0.90 | ELANE (0.68) | ELANECTSGCMA1 | |
| SCHEMBL13924699 | 0.89 | ELANE (0.56) | ELANECTSG | |
| SCHEMBL18880040 | 0.88 | ELANE (0.66) | ELANECTSGCMA1 | |
| SCHEMBL22686717 | 0.88 | ELANE (0.69) | ELANECTSGCMA1 | |
| SCHEMBL20943172 | 0.88 | ELANE (0.69) | ELANECTSGCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116838-A1 | NEOCARZILIN DERIVATIVES AS ANTIMETASTATIC AGENTS | PURDUE RESEARCH FOUNDATION (US) | 2026-04-30 | — | — | US | disclosed |
| US-12612631-B2 | Small RNA medicament for prevention and treatment of inflammation-related diseases and combination thereof | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2026-04-28 | — | — | US | disclosed |
| EP-4004548-B1 | METHODS OF TREATING AND DIAGNOSING LUNG CANCER | YEDA RES & DEV (IL) | 2026-01-14 | — | — | EP | disclosed |
| US-20250354993-A1 | METHODS OF TREATING AND DIAGNOSING LUNG CANCER | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-11-20 | — | — | US | disclosed |
| EP-3713918-B1 | SULFASALAZINE SALTS, PRODUCTION PROCESSES AND USES | MEDAC GES FUER KLINISCHE SPEZIALPRAEPARATE MBH (DE) | 2025-07-23 | — | — | EP | disclosed |
| US-20250223351-A1 | Compounds | MEDIMMUNE LTD (GB) | 2025-07-10 | — | — | US | disclosed |
| US-20250197401-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-19 | — | — | US | disclosed |
| EP-3960858-B1 | SMALL RNA MEDICAMENT FOR PREVENTION AND TREATMENT OF INFLAMMATION-RELATED DISEASES AND COMBINATION THEREOF | BEIJING BAISHIHEKANG PHARMACEUTICAL TECH BSJPHARMA CO LTD (CN) | 2025-05-07 | — | — | EP | disclosed |
| US-12274706-B2 | Pharmaceutical composition for oral administration containing sulfasalazine and/or a sulfasalazine organic salt, production process and use | MEDAC GESELLSCHAFT FUER KLINISCHE (DE) | 2025-04-15 | — | — | US | disclosed |
| EP-4509496-A2 | SULFASALAZINE SALTS, PRODUCTION PROCESSES AND USES | medac Gesellschaft für klinische Spezialpräparate mbH (DE) | 2025-02-19 | — | — | EP | disclosed |
| EP-1919493-B1 | USE OF SPECIFIC TRIFLUOROMETHYL KETONES FOR PREVENTING AND TREATING PANCREATITIS | LERCH MARKUS M (DE) | 2014-07-30 | — | — | EP | disclosed |
| US-20090042969-A1 | Use of Specific Trifluoromethyl Ketones for Preventing and Treating Pancreatitis | ERNST-MORITZ-ARNDT-UNIVERSITAT GREIFSWALD (DE) | 2009-02-12 | — | — | US | disclosed |
| US-6037363-A | Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase | ZENECA LIMITED (GB) | 2000-03-14 | — | — | US | disclosed |
| US-6037363-A | Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase | ZENECA LIMITED (GB) | 2000-03-14 | — | — | US | disclosed |
| US-5907043-A | Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase | ZENECA LIMITED (GB) | 1999-05-25 | — | — | US | disclosed |
| US-5907043-A | Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase | ZENECA LIMITED (GB) | 1999-05-25 | — | — | US | disclosed |
| EP-0743953-B1 | DIASTEREOMERIC PURE TRIFLUOROMETHYL KETONE PEPTIDE DERIVATIVES AS INHIBITORS OF HUMAN LEUKOCYTE ELASTASE | ZENECA LTD (GB) | 1998-12-02 | — | — | EP | disclosed |
| US-5739157-A | Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase | ZENECA LIMITED (GB) | 1998-04-14 | — | — | US | disclosed |
| US-5739157-A | Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase | ZENECA LIMITED (GB) | 1998-04-14 | — | — | US | disclosed |
| WO-1995021855-A1 | DIASTEREOMERIC PURE TRIFLUOROMETHYL KETONE PEPTIDE DERIVATIVES AS INHIBITORS OF HUMAN LEUKOCYTE ELASTASE | ZENECA LIMITED (GB) | 1995-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042969-A1 | Use of Specific Trifluoromethyl Ketones for Preventing and Treating Pancreatitis | PNLIP, AMY2A, FABP2 | ELANE 19/4885CTSG 164/4885CMA1 183/4885 |
| US-12612631-B2 | Small RNA medicament for prevention and treatment of inflammation-related diseases and combination thereof | EIF2AK2, IL1A, IRF3 | ELANE 541/4885CTSG 1633/4885CMA1 925/4885 |
| US-20250197401-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | ELANE 2331/4885CTSG 1394/4885CMA1 103/4885 |
| US-20260116838-A1 | NEOCARZILIN DERIVATIVES AS ANTIMETASTATIC AGENTS | SLC75A1, SLC18A3, SLC8A1 | ELANE 2086/4885CTSG 1421/4885CMA1 733/4885 |
| US-12274706-B2 | Pharmaceutical composition for oral administration containing sulfasalazine and/or a sulfasalazine organic salt, production process and use | SI, SOST, SLC10A2 | ELANE 1988/4885CTSG 1097/4885CMA1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.